Put Options

17 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$3.17 - $6.17 $236,799 - $460,899
-74,700 Reduced 83.74%
14,500 $57,000
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $193,856 - $639,352
46,600 Added 109.39%
89,200 $497,000
Q2 2021

Aug 06, 2021

SELL
$16.52 - $20.4 $150,332 - $185,640
-9,100 Reduced 17.6%
42,600 $742,000
Q1 2021

May 14, 2021

BUY
$16.56 - $25.46 $569,664 - $875,824
34,400 Added 198.84%
51,700 $1.01 Million
Q4 2020

Feb 12, 2021

SELL
$15.77 - $19.03 $64,657 - $78,023
-4,100 Reduced 19.16%
17,300 $310,000
Q3 2020

Nov 13, 2020

SELL
$16.59 - $24.79 $160,923 - $240,463
-9,700 Reduced 31.19%
21,400 $361,000
Q2 2020

Aug 13, 2020

SELL
$16.86 - $23.44 $3,372 - $4,688
-200 Reduced 0.64%
31,100 $697,000
Q1 2020

May 11, 2020

SELL
$14.47 - $27.96 $276,377 - $534,036
-19,100 Reduced 37.9%
31,300 $565,000
Q4 2019

Feb 12, 2020

BUY
$15.87 - $23.12 $355,488 - $517,888
22,400 Added 80.0%
50,400 $1.05 Million
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $121,752 - $261,144
7,200 Added 34.62%
28,000 $501,000
Q2 2019

Aug 20, 2019

BUY
$31.0 - $36.3 $282,100 - $330,330
9,100 Added 77.78%
20,800 $740,000
Q1 2019

May 15, 2019

SELL
$31.58 - $46.35 $129,478 - $190,035
-4,100 Reduced 25.95%
11,700 $393,000
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $526,439 - $980,045
-17,300 Reduced 52.27%
15,800 $531,000
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $984,952 - $1.45 Million
21,200 Added 178.15%
33,100 $2.02 Million
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $1.44 Million - $2.71 Million
-25,000 Reduced 67.75%
11,900 $1.26 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $59,852 - $157,300
-2,600 Reduced 6.58%
36,900 $2.2 Million
Q3 2017

Nov 15, 2017

BUY
$17.79 - $24.0 $702,705 - $948,000
39,500
39,500 $948,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $242M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.